

Artificial Intelligence

Anticipating the Opportunities and the Challenges for Therapeutic Development

M. Khair ElZarrad

Office of Medical Policy, CDER

The views in this presentation do not necessarily represent the policies of FDA

Disclosures: None

Convergence of Large Data Sources and Powerful Computing Capabilities





How AI, machine learning and deep learning fit together (Source: Prowess)



3D MRI 150M

425K

Health Data are Available BUT Needs



Structure, Organization, Verification, Cleaning

AI CAN HELP

It is estimated that by 2015, the average hospital will generate



fographic courtesy of NetApp

NetApp

20-40%

80%

665TB

3GB

Digital Health Explosion + Genomic Data are Increasingly Available





Why does the FDA cares?

FDA U.S. FOOD & DRUG

- 1. Potential to help advance every phase of drug development
 - Discovery and target identification
 - Preclinical
 - Clinical
 - Post-market
- 2. Key to FDA's efforts on multiple fronts (Real-world evidence, mHealth, etc.)
- 3. Capabilities for facilitating and refining

Artificial Intelligence for Drug Discovery

The future of real-world evidence

r better medicines faster.

Biopharma companies focus on end-to-end, Al-driven, internally developed solutions

medicine

Brett Davis

ARTICLES

Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning

Nicolas Coudray^{® 1,2,9}, Paolo Santiago Ocampo^{3,9}, Theodore Sakellaropoulos⁴, Navneet Narula³, Matija Snuderl³, David Fenyö^{5,6}, Andre L. Moreira^{3,7}, Narges Razavian^{® 8*} and Aristotelis Tsirigos^{® 1,3*}



DEVELOPMENT

Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality

Rebecca A. Miksad¹ and Amy P. Abernethy¹

Why does the FDA cares? (cont.)



Big Pharma cannot find skilled AI researchers

- 1. Increasing need for relevant expertise
- 2. Understanding the hype vs. reality in necessary
- 3. Importance of establishing standards and shared understanding among stakeholders



BIG PHARMA WORK-AROUNDS:

- Train in-house experimental pharmacologists in computer science:
- Cultivate "data curators" from existing pool of scientists to act as interface between experimental pharmacologists and computer scientists:
- Outsource to AI (deep learning) companies.

DESIRED BUT HARD-TO-FIND ENGINEERS:

Computer software engineers with skills in deep learning

Slide by Gerry Higgins, M.D., Ph.D. University of Michigan.

The Great Potential for AI In Therapeutic Development FDA



Using artificial intelligence to improve early breast cancer detection

Model developed at MIT's Commuter Options and Antificial Intelligence I also

January 17, 2018

Artificial Intelligence in Manufacturing, Pharma, and Financial Services



Executive leaders need to examine practical use cases to put AI to work in their enterpris by their industry.

wajaj technicai institute, At-rurat At-Awsat technicai Univers

abcinj.ame7@atu.edu.iq

KEYWORDS: Rheumatoid Arthritis, Artificial Intelligence, Diseas



MUST READ: Apple iPhone XR: Three features I love, and one I hate

Al is going to transform the pharmaceutical industry. Here's how.

From lowering risk during drug trials to better study design and faster results, Big Data, the cloud, and AI are transforming how medicine gets made.

FDA is already seeing the use of AI



experienc



News & Events

Home > News & Events > Newsroom > Press Announcements

FDA News Release

FDA permits marketing of artificial intelligencebased device to detect certain diabetes-related eye problems





FDA approves AI-powered diagnostic that doesn't need a doctor's help



APR 12 MORE ON QUALITY AND SAFETY

FDA approves first AI tool for detecting retinopathy, NIH shows machine learning success in imaging

New technologies bring the promise of earlier detection and automation, both with an eye on lowering costs.

Al can be Helpful in Exploring the Use of Real-World Data

Working Definitions

- Real-World Data (RWD) are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources.
- Real-World Evidence (RWE) is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD.

RWE = RWD + Analytics





Understanding the Complexities



Opinion | Ruth Bader Hat Guy? Let Our Algorithm Choose Your Hallo... Machine learning has a spooky side. These algorithmically generated Halloween costumes show how artificial intelligence can reinforce human... nytimes.com Sometimes, the ways algorithms work can have unexpected and disastrous consequences. In 2013, M.I.T. researchers trained an algorithm that was supposed to figure out how to <u>sort a list of numbers</u>. The humans told the algorithm that the goal was to reduce sorting errors, so the program deleted the list entirely, leaving <u>zero sorting errors</u>. And in 1997, <u>another algorithm</u> was supposed to learn to land an airplane on an aircraft carrier as gently as possible. Instead, it discovered that in its simulation it could land the plane with such huge force that the simulation couldn't store the measurement, and would register zero force instead.

- Al prediction algorithms predict the most likely decision or answer that might be achieved using the input data (not necessarily the accurate answer).
- Al predictions and solutions could reflect flaws in algorithms and datasets and provide unpredictable "solutions".

FDA

What is needed?

- FDA
- Understanding the functions and tasks that lend themselves to AI adoption and those that do not
- Shared understanding of principles and approaches that are essential in designing and adopting AI systems (beyond the hype)
 - The need for a quality continuum in the design of AI systems (data and algorithms) to avoid "Garbage in, Garbage out."
 - The need to understand that AI is not necessarily the silver bullet for everything those designing algorithms (and teaching) the machines can't comprehend or impute all of the essential variables.
 - $\circ~$ AI systems can be limited by many factors
 - Learning data sets are imperfect

□ Algorithms have biases and assumptions impeded – can we control for that?, how?



What is needed? (cont.)

- A convergence of multidisciplinary expertise to address the evolution of AI
 - Computer science alone will not produce breakthrough AI systems for drug development
 - We need educational and training programs that connect essential disciplines and provide trainees with the needed skills
- Pilots to explore the utility of AI systems Evaluate successes and failures
 - Failure here is not a standard concept failure is an integral part of machine learning/training. Data from failures in a learning AI system = better AI system.
 - Transparency is key.

Food for thought



- This is a rapidly evolving area we must proactively engage as a community, anticipate innovations, and prepare to respond effectively.
- The FDA is eager to work with all stakeholders to facilitate innovations and shared understanding, and ultimately improve and protect public health

Rapid technological advances call for a proactive engagement by all stakeholders



Thank you!